Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
CARTITUDE-1 study: Are responses with cilta-cel deep and durable?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Deepu Madduri, Icahn School of Medicine at Mount Sinai, New York, US, about the CARTITUDE-1 study. We asked, Are responses with ciltacabtagene autoleucel (cilta-cel) deep and durable? Madduri discusses the preliminary data from the CARTITUDE-1 study evaluating cilta-cel in patients with relapsed/refractory multiple myeloma.
Idecabtagene vicleucel (ide-cel) updated findings in heavily pretreated myeloma ...
In an interview with Targeted Oncology, Yi Lin, MD, PhD discussed the updated findings from the CRB-401 study of idecabtagene vicleucel as treatment of patients with relapsed/refractory multiple myeloma.
Latest updates in myeloma: key takeaways from ASH 2020
Daniel AuClair, PhD, Multiple Myeloma Research Foundation, Norwalk, CT, discusses recent advances in multiple myeloma research that were presented at ASH 2020.
ASH 2020 | CRB-401: ide-cel for R/R multiple myeloma
In this Video, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the Phase I CRB-401 (NCT02658929) study, a non-randomized, open-label, multi-site study of idecabtagene vicleucel in adults with relapsed/refractory (R/R) multiple myeloma.
ASH 2020 | CARTITUDE-1: latest data & CRS in myeloma treated with cilta-cel
In this Video, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, talks on CARTITUDE-1 (NCT03548207), a study which investigated the use of cilta-cel in relapsed/refractory (R/R) multiple myeloma and highlights cytokine release syndrome (CRS) in those treated.